Woodline Partners’s AN2 Therapeutics ANTX Stock Holding History

Woodline Partners’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Sell	459,805 -533,866	-54%	-$2.3M	0.01%	826
2026 Q1	$3.4M	Buy	993,671 +847,700	+581%	+$1.75M	0.01%	728
2025 Q4	$166K	Buy	+145,971	New	+$170K	﹤0.01%	1003
2023 Q1	–	Sell	-107,300	Closed	-$1.02M	–	632
2022 Q4	$1.02M	Buy	107,300 +31,155	+41%	+$417K	0.01%	541
2022 Q3	$1.32M	Sell	76,145 -31,155	-29%	-$363K	0.02%	511
2022 Q2	$832K	Sell	107,300 -42,700	-28%	-$565K	0.01%	532
2022 Q1	$2.26M	Buy	+150,000	New	+$2.28M	0.04%	365

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Woodline Partners's ANTX Position: Q2 2026 in Review

Woodline Partners reduced its AN2 Therapeutics (ANTX) stake by 54% in Q2 2026, selling an estimated $2.3M and leaving 459,805 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #826.

Woodline Partners first reported a position in ANTX in Q1 2022 and has held it in 7 quarters since. The position peaked at $3.4M in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Woodline Partners held 459,805 shares of AN2 Therapeutics worth $2.23M as of Q2 2026.
Woodline Partners sold 533,866 AN2 Therapeutics shares in Q2 2026, an estimated $2.3M.
AN2 Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #826 holding.
Woodline Partners first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 7 quarters since.
Woodline Partners's AN2 Therapeutics position peaked at $3.4M in Q1 2026.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.